Novartis Presents New Data of Zolgensma in P-III Studies in Symptomatic Children with SMA at EAN2021

 Novartis Presents New Data of Zolgensma in P-III Studies in Symptomatic Children with SMA at EAN2021

Shots:

  • The two-copy cohort of P-III SPR1NT study involves evaluating safety & efficacy of Zolgensma (one-time IV infusion) aged ≤6wks. in patients with a genetic diagnosis of SMA & 2 or 3 copies of SMN2
  • The trial met its 1EP & 2EPs i.e 100% of patients achieved event-free survival without respiratory or nutritional support & sit independently for ≥30 seconds, including 79% achieved milestone within WHO window of normal development., 64% walk independently, 100% achieved or maintained CHOP INTEND score of ≥58
  • The 82% children in the P-III STR1VE-EU trial for Zolgensma showed improvements in motor function, not observed in the natural history of SMA Type 1

Click here to­ read full press release/ article | Ref: Globe Newswire | Image: BioProcess International

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post